These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 20965459)

  • 1. Outpatient percutaneous coronary interventions: hospital and health system costs saving while maintaining patient safety.
    Popescu AM; Weintraub WS
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1020-1. PubMed ID: 20965459
    [No Abstract]   [Full Text] [Related]  

  • 2. Economic impact of same-day home discharge after uncomplicated transradial percutaneous coronary intervention and bolus-only abciximab regimen.
    Rinfret S; Kennedy WA; Lachaine J; Lemay A; Rodés-Cabau J; Cohen DJ; Costerousse O; Bertrand OF
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1011-9. PubMed ID: 20965458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. There is no place like home after successful percutaneous coronary intervention.
    Gilchrist IC
    Catheter Cardiovasc Interv; 2009 Dec; 74(7):1017-8. PubMed ID: 19953518
    [No Abstract]   [Full Text] [Related]  

  • 4. Drive-through angioplasty: is it safe or necessary?
    Mixon TA; Dehmer GJ
    Circulation; 2006 Dec; 114(24):2578-80. PubMed ID: 17159072
    [No Abstract]   [Full Text] [Related]  

  • 5. [Abciximab (c7E3)--a new monoclonal antibody--from the pharmaco-economic viewpoint. Initial reports from the literature].
    Sturm C
    Med Klin (Munich); 1996 Nov; 91(11):735-8. PubMed ID: 9036301
    [No Abstract]   [Full Text] [Related]  

  • 6. Bolus-only versus bolus + infusion of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention.
    Kini AS; Chen VH; Krishnan P; Lee P; Kim MC; Mares A; Suleman J; Moreno PR; Sharma SK
    Am Heart J; 2008 Sep; 156(3):513-9. PubMed ID: 18760134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emergency coronary bypass grafting for failed percutaneous coronary artery stenting: increased costs and platelet transfusion requirements after the use of abciximab.
    Alvarez JM
    J Thorac Cardiovasc Surg; 1998 Feb; 115(2):472-3. PubMed ID: 9475547
    [No Abstract]   [Full Text] [Related]  

  • 8. Long term efficacy of abciximab bolus-only compared to abciximab bolus and infusion after transradial coronary stenting.
    Bagur R; Bertrand OF; Rodés-Cabau J; Larose E; Rinfret S; Nguyen CM; Noel B; Larochellière RD; Poirier P; Costerousse O; Roy L
    Catheter Cardiovasc Interv; 2009 Dec; 74(7):1010-6. PubMed ID: 19753635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet glycoprotein IIb/IIIa receptor inhibitors--end of an era?
    Roffi M; Mukherjee D
    Eur Heart J; 2008 Feb; 29(4):429-31. PubMed ID: 18276614
    [No Abstract]   [Full Text] [Related]  

  • 10. Drug-eluting stents: more dollars than sense?
    Garg S; Eisenberg MJ
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1188-9. PubMed ID: 20129544
    [No Abstract]   [Full Text] [Related]  

  • 11. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Use of abciximab: comparative economic data.
    Mark DB; Simons TA
    Am Heart J; 1999 May; 137(5):S123-5. PubMed ID: 10220613
    [No Abstract]   [Full Text] [Related]  

  • 12. The use of abciximab during percutaneous coronary angioplasty reduces ischaemic events, but the cost is prohibitive.
    Mayosi BM; Latouf SE; Commerford PJ
    S Afr Med J; 1998 Feb; 88(2):130-1. PubMed ID: 9717492
    [No Abstract]   [Full Text] [Related]  

  • 13. Are stenting and glycoprotein IIb/IIIa blockade of good value in primary percutaneous coronary intervention?
    Cole JH; Weintraub WS
    Circulation; 2003 Dec; 108(23):2831-3. PubMed ID: 14662689
    [No Abstract]   [Full Text] [Related]  

  • 14. Ambulatory transradial percutaneous coronary intervention: a safe, effective, and cost-saving strategy.
    Le Corvoisier P; Gellen B; Lesault PF; Cohen R; Champagne S; Duval AM; Montalescot G; Elhadad S; Montagne O; Durand-Zaleski I; Dubois-Randé JL; Teiger E
    Catheter Cardiovasc Interv; 2013 Jan; 81(1):15-23. PubMed ID: 22744871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abciximab therapy in percutaneous intervention: economic issues in the United States.
    Goklaney AK; Murphy JD; Hillegass WB
    Am Heart J; 1998 Apr; 135(4):S90-7. PubMed ID: 9539499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The benefits and risks of abciximab, eptifibatide, or tirofiban during PCI: class effects or do they differ?
    Zijlstra F
    Catheter Cardiovasc Interv; 2009 Feb; 73(2):222-3. PubMed ID: 19156883
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost and outcomes analysis of abciximab use in a community teaching hospital.
    Abernathy GB; Hewitt KK
    Am J Health Syst Pharm; 1998 Dec; 55(24 Suppl 4):S35-7. PubMed ID: 9872696
    [No Abstract]   [Full Text] [Related]  

  • 18. Impact of abciximab versus tirofiban on hospital length of stay for PCI patients.
    Lage MJ; Barber BL; McCollam PL; Bala M; Scherer J
    Catheter Cardiovasc Interv; 2001 Mar; 52(3):298-305. PubMed ID: 11246240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized study comparing same-day home discharge and abciximab bolus only to overnight hospitalization and abciximab bolus and infusion after transradial coronary stent implantation.
    Bertrand OF; De Larochellière R; Rodés-Cabau J; Proulx G; Gleeton O; Nguyen CM; Déry JP; Barbeau G; Noël B; Larose E; Poirier P; Roy L;
    Circulation; 2006 Dec; 114(24):2636-43. PubMed ID: 17145988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elective or selective use of abciximab?
    Butler R; Samani NJ
    Lancet; 2000 Feb; 355(9205):755. PubMed ID: 10703832
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.